SCHEMBL10244071

SCHEMBL10244071

COC(=O)NCCNC(C)c1ccn(C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
MC4R P32245 1/20 0.33
RRM1 P23921 1/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A3 Q01959 2/20 0.32
EPHX1 P07099 1/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
MAPT P10636 1/20 0.32
ALDH1A1 P00352 2/20 0.31
LMNA P02545 2/20 0.31
HTT P42858 2/20 0.31
APAF1 O14727 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244577 0.77 RAB9A (0.38) SMN1; SMN2ALDH1A1HTTHSD17B10KMT2A
SCHEMBL10244285 0.77 ESR1 (0.42) SMN1; SMN2RRM1SLC6A2SLC6A4SLC6A3
SCHEMBL10243630 0.76 EPHX1 (0.31) TSHRSMN1; SMN2EPHX1MTNR1AMTNR1B
SCHEMBL10243520 0.75 RAB9A (0.38) TSHRSMN1; SMN2MC4RMTNR1AMTNR1B
SCHEMBL335282 0.74 CYP3A4 (0.36) SMN1; SMN2SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL10243815 0.74 KMT2A (0.41) SMN1; SMN2RRM1MTNR1AMTNR1BALDH1A1
SCHEMBL10243841 0.74 ADRB2 (0.39) TSHRSMN1; SMN2RRM1SLC6A2SLC6A4
SCHEMBL10243724 0.73 KMT2A (0.44) SMN1; SMN2MAPTALDH1A1HTTKMT2A
SCHEMBL10244023 0.73 HDAC3 (0.46) MC4RALDH1A1LMNAKMT2AACACB
SCHEMBL10243646 0.72 EPHX2 (0.41) TSHRSMN1; SMN2LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 TSHR 1567/4885SMN1; SMN2 3120/4885MC4R 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.